The estimated Net Worth of Andrew D Sklawer is at least $293 Tausend dollars as of 17 May 2021. Mr. Sklawer owns over 15,375 units of Brickell Biotech Inc stock worth over $292,869 and over the last 5 years he sold BBI stock worth over $0. In addition, he makes $0 as Co-Founder, Chief Operating Officer und Secretary at Brickell Biotech Inc.
Andrew has made over 3 trades of the Brickell Biotech Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 15,375 units of BBI stock worth $12,300 on 17 May 2021.
The largest trade he's ever made was exercising 20,000 units of Brickell Biotech Inc stock on 16 March 2021 worth over $47,000. On average, Andrew trades about 6,917 units every 47 days since 2020. As of 17 May 2021 he still owns at least 124,625 units of Brickell Biotech Inc stock.
You can see the complete history of Mr. Sklawer stock trades at the bottom of the page.
Andrew D. Sklawer is Co-Founder, Chief Operating Officer, Secretary of the Company. Mr. Sklawer has served as Brickell’s Chief Operating Officer and Secretary since its inception in 2009 and is one of its founders. Prior to co-founding Brickell, Mr. Sklawer served as the Head of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company that was acquired by Kadmon Corporation in 2011. Prior to joining Concordia, Mr. Sklawer held various positions at Verid, Inc., a developer of security technology prior to its acquisition by EMC Corporation. Mr. Sklawer holds a B.A. in marketing from the University of Florida and earned his M.B.A. from the University of Miami. Mr. Sklawer currently serves as a board member for StartUp FIU, a Florida International University platform that supports researchers, inventors, innovators, and entrepreneurs to conceive, launch, and scale solutions, is a member of the Advisory Committee of Advancing Innovation in Dermatology Accelerator Fund and is a board member of the Colorado BioScience Association.
Andrew Sklawer is 36, he's been the Co-Founder, Chief Operating Officer und Secretary of Brickell Biotech Inc since 2019. There are 15 older and 2 younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.
Andrew's mailing address filed with the SEC is C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102, BOULDER, CO, 80301.
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi und Gary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Brickell Biotech Inc executives and other stock owners filed with the SEC include: